AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
135.75
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT
AstraZeneca Revenue
In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth. AstraZeneca had revenue of $14.89B in the quarter ending December 31, 2024, with 23.84% growth.
Revenue
54.07B
Revenue Growth
+18.03%
P/S Ratio
3.95
Revenue / Employee
573.41K
Employees
94,300
Market Cap
213.42B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
AstraZeneca News
- 20 hours ago - Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move? - Benzinga
- 23 hours ago - Drug firm bosses call for price increases in Europe amid tariff uncertainty - Evening Standard
- 1 day ago - Tempus expands partnership with AstraZeneca to build oncology model - Seeking Alpha
- 1 day ago - Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology - Business Wire
- 1 day ago - AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments - Reuters
- 1 day ago - AstraZeneca rejoins leading U.S. drug lobby group after two-year absence - Reuters
- 3 days ago - AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha
- 3 days ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire